Dina A Schott1, Willem J M Gerver2, Constance T R M Stumpel3. 1. Department of Paediatrics, Zuyderland Medical Centre, Heerlen, the Netherlands. 2. Department of Paediatrics Endocrinology, Maastricht UMC+, Maastricht, the Netherlands. 3. Department of Clinical Genetics and GROW - School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, the Netherlands.
Abstract
BACKGROUND/AIMS: Kabuki syndrome (KS) is a rare genetic malformation syndrome, resulting in characteristic features such as short stature. We investigate whether growth hormone (GH) treatment increases linear height and influences body proportions in KS children. METHODS: In this prospective study, 18 genetically confirmed prepubertal KS children (9 females and 9 males) aged from 3.8 to 10.1 years (mean 6.8 ± 2.1 years) were treated with recombinant human GH (rhGH) for 1 year. Calculations for height, height velocity, BMI, sitting height, and subischial leg length were made. Bone age, insulin-like growth factor (IGF-I), and IGF binding protein 3 (IGFBP-3) were also measured. RESULTS: This study showed an increase in height standard deviation score (SDS) for the whole group from -2.40 to -1.69 (p < 0.05) after 1 year of rhGH treatment. The change in height SDS within 1 year was >0.7 SDS for 10 subjects and >0.5 SDS for 3 subjects. The mean IGF-I SDS at the start of the study was -0.70 (±1.07), which increased after 12 months to 1.41 (±0.91) (p < 0.05). KS children who received rhGH at a younger age displayed significantly greater increases in height than those who started when they were older. The same was true for both gene mutation KMT2D versus KDM6A and for GH deficiency versus non-GH deficiency KS children (p < 0.05). Throughout the course of rhGH treatment, the subjects' body proportions remained normal. CONCLUSIONS: All participants experienced catch-up growth during the year of rhGH treatment, but without an influence on body proportions.
BACKGROUND/AIMS: Kabuki syndrome (KS) is a rare genetic malformation syndrome, resulting in characteristic features such as short stature. We investigate whether growth hormone (GH) treatment increases linear height and influences body proportions in KS children. METHODS: In this prospective study, 18 genetically confirmed prepubertal KS children (9 females and 9 males) aged from 3.8 to 10.1 years (mean 6.8 ± 2.1 years) were treated with recombinant human GH (rhGH) for 1 year. Calculations for height, height velocity, BMI, sitting height, and subischial leg length were made. Bone age, insulin-like growth factor (IGF-I), and IGF binding protein 3 (IGFBP-3) were also measured. RESULTS: This study showed an increase in height standard deviation score (SDS) for the whole group from -2.40 to -1.69 (p < 0.05) after 1 year of rhGH treatment. The change in height SDS within 1 year was >0.7 SDS for 10 subjects and >0.5 SDS for 3 subjects. The mean IGF-ISDS at the start of the study was -0.70 (±1.07), which increased after 12 months to 1.41 (±0.91) (p < 0.05). KS children who received rhGH at a younger age displayed significantly greater increases in height than those who started when they were older. The same was true for both gene mutation KMT2D versus KDM6A and for GH deficiency versus non-GH deficiency KSchildren (p < 0.05). Throughout the course of rhGH treatment, the subjects' body proportions remained normal. CONCLUSIONS: All participants experienced catch-up growth during the year of rhGH treatment, but without an influence on body proportions.
Authors: Jill A Fahrner; Wan-Ying Lin; Ryan C Riddle; Leandros Boukas; Valerie B DeLeon; Sheetal Chopra; Susan E Lad; Teresa Romeo Luperchio; Kasper D Hansen; Hans T Bjornsson Journal: JCI Insight Date: 2019-10-17
Authors: Sietse M Aukema; Selina Glaser; Mari F C M van den Hout; Sonja Dahlum; Marinus J Blok; Morten Hillmer; Julia Kolarova; Raf Sciot; Dina A Schott; Reiner Siebert; Constance T R M Stumpel Journal: Fam Cancer Date: 2022-07-19 Impact factor: 2.446
Authors: George Stoyle; Siddharth Banka; Claire Langley; Elizabeth A Jones; Indraneel Banerjee Journal: Endocrinol Diabetes Metab Case Rep Date: 2018-08-23
Authors: Christian Huisman; Young A Kim; Shin Jeon; Bongjin Shin; Jeonghoon Choi; Su Jeong Lim; Sung Min Youn; Younjung Park; Medha K C; Sangsoo Kim; Soo-Kyung Lee; Seunghee Lee; Jae W Lee Journal: Nat Commun Date: 2021-01-11 Impact factor: 14.919
Authors: Francesca Di Candia; Paolo Fontana; Pamela Paglia; Mariateresa Falco; Carmen Rosano; Carmelo Piscopo; Gerarda Cappuccio; Maria Anna Siano; Daniele De Brasi; Claudia Mandato; Ilaria De Maggio; Gabriella Maria Squeo; Matteo Della Monica; Gioacchino Scarano; Fortunato Lonardo; Pietro Strisciuglio; Giuseppe Merla; Daniela Melis Journal: Eur J Pediatr Date: 2021-07-07 Impact factor: 3.183